SMT201600040B - Rilascio non covalente peptide-mediato di agenti attivi attraverso la barriera emato-encefalica - Google Patents

Rilascio non covalente peptide-mediato di agenti attivi attraverso la barriera emato-encefalica

Info

Publication number
SMT201600040B
SMT201600040B SM201600040T SM201600040T SMT201600040B SM T201600040 B SMT201600040 B SM T201600040B SM 201600040 T SM201600040 T SM 201600040T SM 201600040 T SM201600040 T SM 201600040T SM T201600040 B SMT201600040 B SM T201600040B
Authority
SM
San Marino
Prior art keywords
barrier
emathyral
active agents
mediated release
covalent peptide
Prior art date
Application number
SM201600040T
Other languages
English (en)
Inventor
Geoffry L Curran
Gobinda Sarkar
Joseph F Poduslo
Robert B Jenkins
Val J Lowe
Eric W Mahlum
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of SMT201600040B publication Critical patent/SMT201600040B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
SM201600040T 2009-07-14 2016-02-11 Rilascio non covalente peptide-mediato di agenti attivi attraverso la barriera emato-encefalica SMT201600040B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22541209P 2009-07-14 2009-07-14
PCT/US2010/041924 WO2011008823A2 (en) 2009-07-14 2010-07-14 Peptide-mediated non-covalent delivery of active agents across the blood brain barrier

Publications (1)

Publication Number Publication Date
SMT201600040B true SMT201600040B (it) 2016-02-25

Family

ID=43450155

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600040T SMT201600040B (it) 2009-07-14 2016-02-11 Rilascio non covalente peptide-mediato di agenti attivi attraverso la barriera emato-encefalica

Country Status (11)

Country Link
US (4) US20120107243A1 (it)
EP (2) EP2453923B1 (it)
BR (1) BR112012000908A2 (it)
DK (1) DK2453923T3 (it)
ES (1) ES2562463T3 (it)
HR (1) HRP20160136T1 (it)
HU (1) HUE026708T2 (it)
PL (1) PL2453923T3 (it)
SI (1) SI2453923T1 (it)
SM (1) SMT201600040B (it)
WO (1) WO2011008823A2 (it)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2368941T3 (es) 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
PL2233156T3 (pl) 2005-07-15 2013-09-30 Angiochem Inc Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
JP5860698B2 (ja) 2008-04-18 2016-02-16 アンジオケム，インコーポレーテッド パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
JP5705118B2 (ja) 2008-10-15 2015-04-22 アンジオケム インコーポレーテッド 薬物送達のためのエトポシドおよびドキソルビシン複合体
EP2346906A4 (en) 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
EP2421562B1 (en) 2009-04-20 2019-03-13 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
PL2453923T3 (pl) 2009-07-14 2016-06-30 Mayo Found Medical Education & Res Niekowalencyjne dostarczanie aktywnych czynników przez barierę krew-mózg przy udziale peptydów
WO2012085622A1 (en) * 2010-12-22 2012-06-28 Fondazione Telethon Therapeutic strategies to treat cns pathology in mucopolysaccharidoses
EP2785379A4 (en) * 2011-11-29 2015-08-19 Mayo Foundation PEPTIDE-MEDIATED RELEASE OF ACTIVE AGENTS OVER THE BLOOD BRAIN BARRIERS
EP2885318A4 (en) 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE DENDRIMER CONJUGATES AND ITS USES
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
JP2017534640A (ja) * 2014-11-10 2017-11-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルファ−ｌ−イズロニダーゼ、イズロン酸−２−スルファターゼおよびアルファガラクトシダーゼａの治療用組成物ならびにそれらの使用方法
US10584321B2 (en) 2015-02-13 2020-03-10 University Of Massachusetts Compositions and methods for transient delivery of nucleases
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
US10072065B2 (en) * 2015-08-24 2018-09-11 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
EP3411059A4 (en) * 2016-02-02 2019-10-16 University Of Massachusetts METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
EP3452074A4 (en) * 2016-05-03 2019-12-11 University of South Florida COMPOSITIONS AND METHOD FOR MODULATING THE ABETA PROTEIN
WO2020072357A1 (en) 2018-10-04 2020-04-09 University Of Rochester Improvement of glymphatic delivery by manipulating plasma osmolarity
KR102320650B1 (ko) * 2019-10-16 2021-11-04 주식회사 시선테라퓨틱스 혈뇌장벽 투과능을 가지는 펩티드 핵산 복합체 및 이를 포함하는 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US5168045A (en) * 1989-08-18 1992-12-01 The Scripps Research Institute Diagnostic systems and methods using polypeptide analogs of apolipoprotein e
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US20030069173A1 (en) 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
EP1039883A4 (en) * 1996-07-09 2001-09-26 Keith A Crutcher METHOD FOR TREATING APOLIPOPROTEIN E CONDITIONAL DISEASES
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1086126A1 (en) 1998-06-10 2001-03-28 The Queen's University of Belfast Cell-permeable peptide
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US20040241164A1 (en) * 2001-08-17 2004-12-02 Bales Kelly Renee Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass
US20040072774A1 (en) 2002-02-23 2004-04-15 Giovanni Manfredi Methods for expressing and targeting mitochondrial-DNA-encoded peptides and uses thereof
WO2003093295A2 (en) 2002-04-30 2003-11-13 University Of North Carolina At Chapel Hill Secretion signal vectors
WO2004015083A2 (en) 2002-08-08 2004-02-19 Insert Therapeutics, Inc. Compositions and uses of motor protein-binding moieties
US20040229219A1 (en) * 2003-04-30 2004-11-18 Gallaher William R. Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)
AU2003286870A1 (en) * 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US20050118204A1 (en) 2003-09-25 2005-06-02 Kazutami Sakamoto Methods for controlling membrane permeability of a membrane permeable substance and screening methods for a membrane permeable substance
US8283444B2 (en) 2003-10-24 2012-10-09 Wake Forest University Non-viral delivery of compounds to mitochondria
DE10355559A1 (de) * 2003-11-21 2005-06-23 Orthogen Ag Transskin
EP1773401B1 (en) 2004-06-21 2013-01-02 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
US7408030B2 (en) 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
KR20080042804A (ko) * 2005-07-19 2008-05-15 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 뇌혈관장벽을 통하여 뇌 암세포 내로 침투하는 운반제 및이의 이용 방법
US20100119528A1 (en) * 2008-01-17 2010-05-13 Gobinda Sarkar Transport of Biologically Active Molecules into a Cell, Mitochondrion, or Nucleus
KR101617790B1 (ko) 2008-02-26 2016-05-03 아파르나 바이오사이언시스 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물
PL2453923T3 (pl) 2009-07-14 2016-06-30 Mayo Found Medical Education & Res Niekowalencyjne dostarczanie aktywnych czynników przez barierę krew-mózg przy udziale peptydów
EP2785379A4 (en) 2011-11-29 2015-08-19 Mayo Foundation PEPTIDE-MEDIATED RELEASE OF ACTIVE AGENTS OVER THE BLOOD BRAIN BARRIERS
WO2016054107A1 (en) 2014-09-29 2016-04-07 Counterpoint Biomedica Llc Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers
US20170007669A1 (en) 2015-07-07 2017-01-12 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of active agents across the blood-brain barrier
US10072065B2 (en) 2015-08-24 2018-09-11 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of immunoglobulins across the blood-brain barrier

Also Published As

Publication number Publication date
PL2453923T3 (pl) 2016-06-30
HRP20160136T1 (hr) 2016-03-11
US20120107243A1 (en) 2012-05-03
EP2453923A2 (en) 2012-05-23
ES2562463T3 (es) 2016-03-04
US20190322723A1 (en) 2019-10-24
BR112012000908A2 (pt) 2019-09-24
US20170145076A1 (en) 2017-05-25
WO2011008823A2 (en) 2011-01-20
HUE026708T2 (en) 2016-07-28
WO2011008823A9 (en) 2011-08-11
EP3000481A2 (en) 2016-03-30
US9597408B2 (en) 2017-03-21
WO2011008823A3 (en) 2011-05-12
US10377813B2 (en) 2019-08-13
EP2453923B1 (en) 2015-11-11
US20140328866A1 (en) 2014-11-06
DK2453923T3 (en) 2016-02-15
SI2453923T1 (sl) 2016-04-29
EP2453923A4 (en) 2013-01-23
EP3000481A3 (en) 2016-05-11

Similar Documents

Publication Publication Date Title
SMT201600040B (it) Rilascio non covalente peptide-mediato di agenti attivi attraverso la barriera emato-encefalica
CY2019031I1 (el) Αναπνευστικη απελευθερωση ενεργων παραγοντων
SMT201500053B (it) 2-Amminobenzimidazol-5-carbossammidi come agenti nati-infiammatori
EP2346734A4 (en) ACTIVE WINGLET
BRPI1010909A2 (pt) "inseticida arilpirrolinas"
BRPI1009315A2 (pt) agentes anti-inflamatórios
BRPI0818874A2 (pt) Liberação de agentes ativos
DK3061445T3 (da) Højkoncentrerede farmaceutiske formuleringer
BRPI1012004A2 (pt) "forma farmacêutica"
LT3360575T (lt) Transderminės farmacinės kompozicijos, apimančios veiksminguosius agentus
BRPI1011601A2 (pt) "antagonista de trajetória de hedgehog de ftalazina dissubstituída"
BRPI1015203A2 (pt) agentes antimicrobianos
PT2448582T (pt) Compostos e composições terapêuticas
EP2419097A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2451274A4 (en) Pharmaceutical compositions
BRPI0916931A2 (pt) agentes terapêuticos
HRP20160579T1 (hr) Spoj indola i njegova farmaceutska upotreba
BRPI0924425A2 (pt) "combinações de substâncias ativas sinergéticas".
SMT201400069B (it) Formulazione farmaceutica
EP2478768A4 (en) AGGREGATE AGAINST PLANT VIRUSES
BRPI1013985A2 (pt) Agentes de proteção
SMT201600041B (it) Agenti terapeutici 713
ITRE20110041A1 (it) Agente sanitario
BRPI1007237A2 (pt) composição farmacêutica compreendendo aleglitazar
BRPI0823402A2 (pt) Formulações farmacêuticas de olmesartan